ZA200300889B - Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia. - Google Patents

Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia.

Info

Publication number: ZA200300889B
Authority: ZA; South Africa
Prior art keywords: trihalomethylphenoxy; hyperuricemia; halophenyl; treatment; acetic acid
Prior art date: 1999-06-04

Application number

ZA200300889A

Other languages

English (en)

Inventor

Kenneth L Luskey

Jian Luo

Original Assignee

Metabolex Inc

Diatex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-04

Filing date

2000-06-02

Publication date

2004-08-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23270381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200300889(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-02 Application filed by Metabolex Inc, Diatex Inc filed Critical Metabolex Inc

2004-08-25 Publication of ZA200300889B publication Critical patent/ZA200300889B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Neurology (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200300889A 1999-06-04 2000-06-02 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia. ZA200300889B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/325,997 US6262118B1 (en)	1999-06-04	1999-06-04	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia

Publications (1)

Publication Number	Publication Date
ZA200300889B true ZA200300889B (en)	2004-08-25

Family

ID=23270381

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
ZA200300888A ZA200300888B (en)	1999-06-04	2000-06-02	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperlipidemia.
ZA200300889A ZA200300889B (en)	1999-06-04	2000-06-02	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia.
ZA200109973A ZA200109973B (en)	1999-06-04	2001-12-04	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
ZA200300888A ZA200300888B (en)	1999-06-04	2000-06-02	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperlipidemia.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ZA200109973A ZA200109973B (en)	1999-06-04	2001-12-04	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia.

Country Status (32)

Country	Link
US (6)	US6262118B1 (xx)
EP (2)	EP1183020B1 (xx)
JP (2)	JP4685300B2 (xx)
KR (2)	KR100779787B1 (xx)
CN (2)	CN1189168C (xx)
AR (1)	AR042574A1 (xx)
AT (2)	ATE524173T1 (xx)
AU (1)	AU775909C (xx)
BR (1)	BR0011342A (xx)
CA (2)	CA2371723C (xx)
CL (1)	CL2011001971A1 (xx)
CO (1)	CO5170453A1 (xx)
CY (1)	CY1112861T1 (xx)
CZ (1)	CZ20014341A3 (xx)
DE (1)	DE60030109T2 (xx)
DK (2)	DK1183020T3 (xx)
ES (2)	ES2269151T3 (xx)
HK (1)	HK1045111B (xx)
HU (1)	HUP0201611A3 (xx)
IL (3)	IL146914A0 (xx)
MX (1)	MXPA01012435A (xx)
NO (1)	NO20015909L (xx)
NZ (2)	NZ515902A (xx)
PE (1)	PE20010220A1 (xx)
PT (2)	PT1183020E (xx)
RU (2)	RU2281762C2 (xx)
SA (1)	SA00210535B1 (xx)
SK (1)	SK17562001A3 (xx)
TW (1)	TWI264303B (xx)
UA (1)	UA74147C2 (xx)
WO (1)	WO2000074666A2 (xx)
ZA (3)	ZA200300888B (xx)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6624194B1 (en) *	1999-06-04	2003-09-23	Metabolex, Inc.	Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7576131B2 (en) *	1999-06-04	2009-08-18	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) *	1999-06-04	2001-07-17	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US20080108825A1 (en) *	1999-11-08	2008-05-08	Theracos, Inc.	Compounds for treatment of inflammation, diabetes and related disorders
US7323496B2 (en) *	1999-11-08	2008-01-29	Theracos, Inc.	Compounds for treatment of inflammation, diabetes and related disorders
US20080103302A1 (en) *	2000-02-04	2008-05-01	Theracos, Inc.	Compounds for treatment of inflammation, diabetes and related disorders
AU2001253373A1 (en) *	2000-04-12	2001-10-30	Puracyp	Compositions and methods for induction of proteins involved in xenobiotic metabolism
PE20020323A1 (es) *	2000-08-22	2002-06-13	Novartis Ag	COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
AU2002251978B2 (en)	2001-02-09	2007-07-19	Merck & Co., Inc.	2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
ATE422884T1 (de) *	2002-06-03	2009-03-15	Novartis Pharma Gmbh	Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
WO2003103633A1 (en) *	2002-06-10	2003-12-18	Elan Pharma International, Ltd.	Nanoparticulate sterol formulations and sterol combinations
CN100525757C (zh) *	2003-06-20	2009-08-12	麦它波莱克斯股份有限公司	α-(苯氧基)苯乙酸衍生物的拆分
MXPA05013981A (es) *	2003-06-20	2006-03-02	Metabolex Inc	Resolucion de derivados de acido a- (fenoxi) fenilacetico.
US7199259B2 (en) *	2003-06-20	2007-04-03	Metabolex, Inc.	Resolution of α-(phenoxy)phenylacetic acid derivatives
US20050054731A1 (en) *	2003-09-08	2005-03-10	Franco Folli	Multi-system therapy for diabetes, the metabolic syndrome and obesity
KR20070011312A (ko) *	2004-02-18	2007-01-24	메타볼렉스, 인코포레이티드	항당뇨병제로서 알파-(트리플루오로메틸-치환된 아릴옥시,아릴아미노, 아릴티오 또는아릴메틸)-트리플루오로메틸-치환된 페닐아세트산 및 이의유도체
US7816367B2 (en)	2004-02-27	2010-10-19	Amgen Inc.	Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
EP1751120A4 (en) *	2004-05-25	2010-05-05	Metabolex Inc	SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND MANUFACTURING METHOD THEREFOR
WO2005115384A2 (en) *	2004-05-25	2005-12-08	Metabolex, Inc.	Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
EP1865778A4 (en) *	2005-03-21	2010-12-08	Metabolex Inc	METHOD FOR AVOIDING OEDEM IN THE TREATMENT OF METABOLISM DISORDER, INFLAMMATORY DISEASES AND CARDIOVASCULAR DISEASES
US8203019B2 (en) *	2005-04-20	2012-06-19	Metabolex, Inc.	Crystalline solid and amorphous forms of (−)- halofenate and methods related thereto
US20090137626A1 (en) *	2005-07-12	2009-05-28	Akira Okuno	Pharmaceutical Composition Containing PPARgamma Agonist
EP1906934A4 (en) *	2005-07-14	2012-03-07	Franco Folli	DAILY DOSAGE SCHEME FOR THE TREATMENT OF DIABETES, OBESITY, METABOLIC SYNDROME AND POLYKYSTIC OVAIRE SYNDROME
US7432394B2 (en) *	2005-09-23	2008-10-07	Metabolex, Inc.	Resolution of α-(phenoxy) phenylacetic acid derivatives with naphthyl-alkylamines
US7714131B2 (en) *	2005-09-23	2010-05-11	Metabolex, Inc.	Process for the stereoselective preparation of (−)-halofenate and derivatives thereof
TW200806285A (en) *	2006-03-30	2008-02-01	Santen Pharmaceutical Co Ltd	Therapeutic agent for keratoconjunctive problem
WO2007127440A2 (en) *	2006-04-27	2007-11-08	Intezyne Technologies, Inc.	Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
KR100788454B1 (ko) *	2006-06-15	2007-12-24	대원제약주식회사	속효성이 증진된 나테글리니드를 유효성분으로 함유하는약제학적 조성물
BRPI0716134A2 (pt)	2006-09-07	2013-09-17	Nycomed Gmbh	tratamento de combinaÇço para diabetes mellitus
WO2009052182A1 (en)	2007-10-15	2009-04-23	Jbs United, Inc.	Method for increasing performance of offspring
WO2008149345A2 (en)	2007-06-04	2008-12-11	Ben-Gurion University Of The Negev Research And Development Authority	Tri-aryl compounds and compositions comprising the same
US20110021468A1 (en) *	2007-07-03	2011-01-27	Joslin Diabetes Center, Inc.	Treatment of cardiovascular disease with salicylates
WO2009046371A1 (en) *	2007-10-05	2009-04-09	Metabolex, Inc.	Methods of treating metabolic diseases
WO2009121940A1 (en) *	2008-04-03	2009-10-08	Janssen Pharmaceutica Nv	Process for the preparation of (-)-(4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester
AR074760A1 (es)	2008-12-18	2011-02-09	Metabolex Inc	Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8299117B2 (en)	2010-06-16	2012-10-30	Metabolex Inc.	GPR120 receptor agonists and uses thereof
WO2014037832A2 (en)	2012-09-06	2014-03-13	Mahesh Kandula	Compositions and methods for the treatment of epilepsy and neurological diseases
CN104066323A (zh) *	2011-11-04	2014-09-24	西玛贝医药公司	用于治疗患者亚群中痛风的方法
US9023856B2 (en)	2011-11-04	2015-05-05	Cymabay Therapeutics, Inc.	Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent
CN109908124A (zh) *	2011-11-04	2019-06-21	西玛贝医药公司	利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法
ES2698396T3 (es) *	2011-11-04	2019-02-04	Cymabay Therapeutics Inc	Métodos para tratar los brotes de gota
US9060987B2 (en)	2011-11-04	2015-06-23	Cymabay Therapeutics, Inc.	Methods for treating gout flares
EP2836209A4 (en) *	2012-04-13	2015-11-25	Cymabay Therapeutics Inc	METHOD FOR THE TREATMENT OF HYPERURICEMIA IN PATIENTS WITH A GOG THROUGH HALOFENATE OR HALOFENIC ACID AND AN INFLAMMATORY INHIBITOR
WO2013168021A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167990A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of depression
EP2847169A4 (en)	2012-05-07	2015-09-30	Cellix Bio Private Ltd	COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS
WO2013168025A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of blood clotting disorders
WO2013167993A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological degenerative disorders
WO2013167991A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic disorders
WO2013168023A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of parkinson's disease
US9403826B2 (en)	2012-05-08	2016-08-02	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory disorders
US9315461B2 (en)	2012-05-10	2016-04-19	Cellix Bio Private Limited	Compositions and methods for the treatment of neurologic diseases
US9321775B2 (en)	2012-05-10	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of moderate to severe pain
WO2013168011A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of chronic pain
CA2873089A1 (en) *	2012-05-10	2013-11-14	Cellixbio Private Limited	Compositions and methods for the treatment of metabolic syndrome
WO2013168014A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of familial amyloid polyneuropathy
US9346742B2 (en)	2012-05-10	2016-05-24	Cellix Bio Private Limited	Compositions and methods for the treatment of fibromyalgia pain
US9394288B2 (en)	2012-05-10	2016-07-19	Cellix Bio Private Limited	Compositions and methods for the treatment of asthma and allergy
US9315478B2 (en)	2012-05-10	2016-04-19	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
US9573927B2 (en)	2012-05-10	2017-02-21	Cellix Bio Private Limited	Compositions and methods for the treatment of severe pain
WO2013168012A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of respiratory disorders
WO2013168016A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic syndrome
US9339484B2 (en)	2012-05-10	2016-05-17	Cellix Bio Private Limited	Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168002A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological conditions
WO2013168033A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neurologic diseases
CA2873098A1 (en)	2012-05-23	2013-11-28	Cellixbio Private Limited	Compositions and methods for the treatment of multiple sclerosis
US9434729B2 (en)	2012-05-23	2016-09-06	Cellix Bio Private Limited	Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175347A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of respiratory disorders
AU2013264894B2 (en)	2012-05-23	2015-11-19	Cellix Bio Private Limited	Compositions and methods for treatment of inflammatory bowel disease
WO2013175377A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of mucositis
WO2013175376A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of local pain
US9108942B1 (en)	2014-11-05	2015-08-18	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en)	2012-08-03	2014-02-06	Mahesh Kandula	Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en)	2012-09-06	2014-03-13	Mahesh Kandula	Compositions and methods for the treatment inflammation and lipid disorders
AU2013311349A1 (en)	2012-09-08	2014-11-27	Cellixbio Private Limited	Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en)	2013-05-15	2016-05-10	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en)	2013-06-04	2018-09-05	Cellixbio Private Limited	Compositions and methods for the treatment of diabetes and pre-diabetes
CN106061940A (zh)	2013-11-05	2016-10-26	本古里安大学内盖夫研究发展局	治疗糖尿病和由其引发的并发疾病的化合物
US9096537B1 (en)	2014-12-31	2015-08-04	Mahesh Kandula	Compositions and methods for the treatment of mucositis
WO2016110865A1 (en)	2015-01-06	2016-07-14	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammation and pain
SG11201706952VA (en)	2014-09-26	2017-10-30	Cellix Bio Private Ltd	Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es)	2014-09-29	2020-12-16	Cellix Bio Private Ltd	Compuestos y composiciones para el tratamiento de esclerosis múltiple
SG11201703369WA (en)	2014-10-27	2017-05-30	Cellix Bio Private Ltd	Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9150557B1 (en)	2014-11-05	2015-10-06	Cellix Bio Private Limited	Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en)	2014-11-05	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Prodrugs of anti-platelet agents
US10208014B2 (en)	2014-11-05	2019-02-19	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological disorders
US9173877B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
US9290486B1 (en)	2014-11-05	2016-03-22	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy
US9284287B1 (en)	2014-11-05	2016-03-15	Cellix Bio Private Limited	Compositions and methods for the suppression of carbonic anhydrase activity
US9932294B2 (en)	2014-12-01	2018-04-03	Cellix Bio Private Limited	Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en)	2014-12-17	2015-12-08	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological diseases
JP6192142B2 (ja) *	2016-09-13	2017-09-06	サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	痛風発赤の治療方法
JP6368756B2 (ja) *	2016-10-20	2018-08-01	サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
CN109369471A (zh) *	2018-12-10	2019-02-22	石家庄度恩医药科技有限公司	一种光学活性R-4-氯-α-(3-三氟甲基苯氧基)苯乙酸的制备方法
WO2021236395A1 (en)	2020-05-18	2021-11-25	Cymabay Therapeutics, Inc.	Cb-0406 choline salt
US20210355065A1 (en)	2020-05-18	2021-11-18	Cymabay Therapeutics, Inc.	CB-0406 tromethamine salt
USD1107573S1 (en) *	2022-08-19	2025-12-30	Honeywell International Inc.	Aerosol sensor

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3517051A (en) *	1964-03-20	1970-06-23	Merck & Co Inc	Phenoxy substituted phenylacetic acids
US3378582A (en) *	1964-03-20	1968-04-16	Merck & Co Inc	(alpha-phenoxy)-and (alpha-phenylthio)-omegaphenyl-alkanoic acids
NL6712585A (xx)	1966-10-03	1968-04-04
US3517050A (en)	1966-10-03	1970-06-23	Merck & Co Inc	Ester and amide derivative of (3-trifluoromethylphenoxy) (4 - halophenyl)acetic acid
DK133742B (da)	1970-10-30	1976-07-12	Merck & Co Inc	Fremgangsmåde til fremstilling af 2-acetamidoethyl-(3-trifluormethylphenoxy)-(4-chlorphenyl)-acetat.
US3923855A (en)	1972-07-13	1975-12-02	Merck & Co Inc	2-sulfonyloxyethyl 3-trifluoromethylphenoxy-4{40 -chlorophenyl acetate
NL7309039A (xx) *	1972-07-13	1974-01-15
US3860628A (en) *	1972-07-13	1975-01-14	Merck & Co Inc	Cyanomethyl(3-trifluoromethylphenoxy)(4-chlorophenyl)acetate
US3953490A (en)	1972-07-13	1976-04-27	Merck & Co., Inc.	Preparation of (3-trifluoromethylphenoxy)(4-chlorophenyl)acetonitrile
NL7309571A (xx)	1972-07-28	1974-01-30
US4110351A (en)	1973-04-02	1978-08-29	Richardson-Merrell Inc.	Hypolipidemic agents RO- or RS- substituted furoic acids, esters and salts
IL48707A0 (en)	1974-12-30	1976-02-29	Synthelabo	Novel phenylacetic acid derivatives,their preparation and pharmaceutical compositions containing them
US4250191A (en) *	1978-11-30	1981-02-10	Edwards K David	Preventing renal failure
US4532135A (en) *	1981-02-09	1985-07-30	Edwards K David G	Renoprotective treatments employing vasodilator compounds
DE3525284A1 (de) *	1985-07-16	1987-01-29	Boehringer Mannheim Gmbh	Neue carbonsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung sowie arzneimittel, die diese verbindungen enthalten
US5028052A (en) *	1990-05-11	1991-07-02	Miller Omer E	Golf mat
DE4111026A1 (de)	1991-04-05	1992-10-08	Boehringer Mannheim Gmbh	Optisch aktive carbonsaeuren sowie diese enthaltende arzneimittel
US5605930A (en)	1991-10-21	1997-02-25	The United States Of America As Represented By The Department Of Health And Human Services	Compositions and methods for treating and preventing pathologies including cancer
JPH0927811A (ja) *	1995-07-13	1997-01-28	Fujitsu Ltd	輻輳監視制御装置
WO1997010813A1 (en)	1995-09-18	1997-03-27	Ligand Pharmaceuticals Incorporated	Ppar gamma antagonists for treating obesity
US5859051A (en)	1996-02-02	1999-01-12	Merck & Co., Inc.	Antidiabetic agents
US5716987A (en) *	1996-06-21	1998-02-10	Bristol-Myers Squibb Company	Prophylactic and therapeutic treatment of skin sensitization and irritation
US6262118B1 (en) *	1999-06-04	2001-07-17	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US6624194B1 (en) *	1999-06-04	2003-09-23	Metabolex, Inc.	Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7576131B2 (en) *	1999-06-04	2009-08-18	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6555577B1 (en)	2000-01-28	2003-04-29	Novo Nordisk A/S	Compounds, their preparation and use
US6576662B2 (en)	2000-05-05	2003-06-10	Dr. Reddy's Laboratories Limited	Compounds having anticancer activity : process for their preparation and pharmaceutical compositions containing them
US6693094B2 (en)	2001-03-22	2004-02-17	Chrono Rx Llc	Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
CN1319938C (zh)	2002-06-20	2007-06-06	阿斯特拉曾尼卡有限公司	治疗胰岛素抵抗的邻位取代的苯甲酸衍生物
DE10308355A1 (de)	2003-02-27	2004-12-23	Aventis Pharma Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
WO2004078113A2 (en) *	2003-03-04	2004-09-16	Pharmacia Corporation	Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
US7199259B2 (en) *	2003-06-20	2007-04-03	Metabolex, Inc.	Resolution of α-(phenoxy)phenylacetic acid derivatives
MXPA05013981A (es)	2003-06-20	2006-03-02	Metabolex Inc	Resolucion de derivados de acido a- (fenoxi) fenilacetico.
US20070207983A1 (en)	2004-03-16	2007-09-06	Nieuwenhuizen Willem F	Use of Sphingolipids in the Treatment and Prevention of Type 2 Diabetes Mellitus, Insulin Resistance and Metabolic Syndrome
WO2007102861A2 (en)	2005-12-02	2007-09-13	Sirtris Pharmaceuticals, Inc.	Modulators of cdc2-like kinases (clks) and methods of use thereof
US7635710B2 (en)	2006-02-15	2009-12-22	Neurim Pharmaceuticals (1991) Ltd.	Pyrone-indole derivatives and process for their preparation

1999
- 1999-06-04 US US09/325,997 patent/US6262118B1/en not_active Expired - Lifetime
2000
- 2000-02-06 UA UA2001129087A patent/UA74147C2/uk unknown
- 2000-06-02 CN CNB008112908A patent/CN1189168C/zh not_active Expired - Fee Related
- 2000-06-02 PT PT00938074T patent/PT1183020E/pt unknown
- 2000-06-02 AT AT05076901T patent/ATE524173T1/de active
- 2000-06-02 CN CNB2004100116574A patent/CN100379412C/zh not_active Expired - Fee Related
- 2000-06-02 RU RU2002100037/04A patent/RU2281762C2/ru not_active IP Right Cessation
- 2000-06-02 KR KR1020067022082A patent/KR100779787B1/ko not_active Expired - Fee Related
- 2000-06-02 HU HU0201611A patent/HUP0201611A3/hu active IP Right Revival
- 2000-06-02 CA CA2371723A patent/CA2371723C/en not_active Expired - Fee Related
- 2000-06-02 EP EP00938074A patent/EP1183020B1/en not_active Expired - Lifetime
- 2000-06-02 NZ NZ515902A patent/NZ515902A/xx unknown
- 2000-06-02 US US09/585,907 patent/US6613802B1/en not_active Expired - Lifetime
- 2000-06-02 KR KR1020017015625A patent/KR100721219B1/ko not_active Expired - Fee Related
- 2000-06-02 IL IL14691400A patent/IL146914A0/xx unknown
- 2000-06-02 CZ CZ20014341A patent/CZ20014341A3/cs unknown
- 2000-06-02 CA CA2751187A patent/CA2751187C/en not_active Expired - Fee Related
- 2000-06-02 AU AU53162/00A patent/AU775909C/en not_active Ceased
- 2000-06-02 ZA ZA200300888A patent/ZA200300888B/xx unknown
- 2000-06-02 NZ NZ528266A patent/NZ528266A/en unknown
- 2000-06-02 ES ES00938074T patent/ES2269151T3/es not_active Expired - Lifetime
- 2000-06-02 HK HK02106591.8A patent/HK1045111B/en not_active IP Right Cessation
- 2000-06-02 PE PE2000000551A patent/PE20010220A1/es not_active Application Discontinuation
- 2000-06-02 PT PT05076901T patent/PT1614418E/pt unknown
- 2000-06-02 DK DK00938074T patent/DK1183020T3/da active
- 2000-06-02 EP EP05076901A patent/EP1614418B1/en not_active Expired - Lifetime
- 2000-06-02 ES ES05076901T patent/ES2371476T3/es not_active Expired - Lifetime
- 2000-06-02 AT AT00938074T patent/ATE336235T1/de active
- 2000-06-02 WO PCT/US2000/015235 patent/WO2000074666A2/en not_active Ceased
- 2000-06-02 JP JP2001501203A patent/JP4685300B2/ja not_active Expired - Fee Related
- 2000-06-02 BR BR0011342-5A patent/BR0011342A/pt not_active Application Discontinuation
- 2000-06-02 MX MXPA01012435A patent/MXPA01012435A/es active IP Right Grant
- 2000-06-02 DK DK05076901.7T patent/DK1614418T3/da active
- 2000-06-02 SK SK1756-2001A patent/SK17562001A3/sk unknown
- 2000-06-02 ZA ZA200300889A patent/ZA200300889B/xx unknown
- 2000-06-02 DE DE60030109T patent/DE60030109T2/de not_active Expired - Lifetime
- 2000-06-02 AR ARP000102742A patent/AR042574A1/es unknown
- 2000-06-03 TW TW089110927A patent/TWI264303B/zh not_active IP Right Cessation
- 2000-06-06 CO CO00041901A patent/CO5170453A1/es not_active Application Discontinuation
- 2000-10-31 US US09/703,487 patent/US6646004B1/en not_active Expired - Lifetime
- 2000-11-15 SA SA00210535A patent/SA00210535B1/ar unknown
2001
- 2001-12-03 NO NO20015909A patent/NO20015909L/no not_active Application Discontinuation
- 2001-12-04 IL IL146914A patent/IL146914A/en not_active IP Right Cessation
- 2001-12-04 ZA ZA200109973A patent/ZA200109973B/en unknown
2003
- 2003-09-10 US US10/660,112 patent/US20050075396A1/en not_active Abandoned
2005
- 2005-10-18 RU RU2005132222/15A patent/RU2005132222A/ru not_active Application Discontinuation
2007
- 2007-01-23 JP JP2007013175A patent/JP4685808B2/ja not_active Expired - Fee Related
- 2007-03-22 US US11/690,026 patent/US20070270490A1/en not_active Abandoned
- 2007-11-25 IL IL187605A patent/IL187605A/en not_active IP Right Cessation
2009
- 2009-07-16 US US12/504,487 patent/US8354448B2/en not_active Expired - Fee Related
2011
- 2011-08-12 CL CL2011001971A patent/CL2011001971A1/es unknown
- 2011-12-12 CY CY20111101227T patent/CY1112861T1/el unknown

Also Published As

Publication number	Publication date
HK1045111B (en)	2006-11-17
US20070270490A1 (en)	2007-11-22
NO20015909L (no)	2002-01-15
RU2281762C2 (ru)	2006-08-20
DK1614418T3 (da)	2011-10-17
PT1183020E (pt)	2006-11-30
PE20010220A1 (es)	2001-02-23
IL146914A0 (en)	2002-08-14
NZ515902A (en)	2004-02-27
EP1183020B1 (en)	2006-08-16
AR042574A1 (es)	2005-06-29
US20050075396A1 (en)	2005-04-07
NZ528266A (en)	2005-07-29
ZA200109973B (en)	2003-02-04
JP4685300B2 (ja)	2011-05-18
WO2000074666A3 (en)	2001-11-08
US6613802B1 (en)	2003-09-02
JP2007099784A (ja)	2007-04-19
WO2000074666A2 (en)	2000-12-14
CA2751187A1 (en)	2000-12-14
IL187605A0 (en)	2008-03-20
CN1189168C (zh)	2005-02-16
JP2003501383A (ja)	2003-01-14
US8354448B2 (en)	2013-01-15
IL187605A (en)	2012-07-31
EP1183020A2 (en)	2002-03-06
KR100721219B1 (ko)	2007-05-22
CA2371723C (en)	2012-08-21
KR20020025063A (ko)	2002-04-03
ATE336235T1 (de)	2006-09-15
ATE524173T1 (de)	2011-09-15
CN1368879A (zh)	2002-09-11
CO5170453A1 (es)	2002-06-27
CN1660060A (zh)	2005-08-31
DE60030109T2 (de)	2007-02-15
TWI264303B (en)	2006-10-21
EP1614418B1 (en)	2011-09-14
CA2751187C (en)	2014-04-22
EP1614418A1 (en)	2006-01-11
DK1183020T3 (da)	2006-11-27
KR100779787B1 (ko)	2007-11-28
AU775909B2 (en)	2004-08-19
SK17562001A3 (sk)	2002-10-08
US6262118B1 (en)	2001-07-17
AU5316200A (en)	2000-12-28
ZA200300888B (en)	2004-06-30
ES2371476T3 (es)	2012-01-03
RU2005132222A (ru)	2007-04-27
KR20060122983A (ko)	2006-11-30
HUP0201611A3 (en)	2003-03-28
NO20015909D0 (no)	2001-12-03
MXPA01012435A (es)	2003-09-10
ES2269151T3 (es)	2007-04-01
US20100093853A1 (en)	2010-04-15
CL2011001971A1 (es)	2012-03-30
HK1087616A1 (en)	2006-10-20
JP4685808B2 (ja)	2011-05-18
BR0011342A (pt)	2002-03-05
CA2371723A1 (en)	2000-12-14
CZ20014341A3 (cs)	2002-11-13
CN100379412C (zh)	2008-04-09
HUP0201611A2 (en)	2002-10-28
IL146914A (en)	2008-07-08
SA00210535B1 (ar)	2006-10-11
HK1045111A1 (en)	2002-11-15
CY1112861T1 (el)	2016-04-13
UA74147C2 (uk)	2005-11-15
US6646004B1 (en)	2003-11-11
AU775909C (en)	2005-06-30
PT1614418E (pt)	2011-11-21
DE60030109D1 (de)	2006-09-28

Publication	Publication Date	Title
ZA200300889B (en)	2004-08-25	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemia.
IL147822A0 (en)	2002-08-14	Benzoic acid derivatives for the treatment of diabetes mellitus
AU4223000A (en)	2000-10-23	Patient sensor for clinical spectrophotometric apparatus
AU2045401A (en)	2001-06-04	Blood vessel catheter
AU7870900A (en)	2001-04-23	Treatment of scar tissue using lipoic acid
HUP0300592A3 (en)	2005-11-28	Process for the preparation of 2-halobenzoic acid derivatives
NO20022087L (no)	2002-06-24	Fremgangsmåte for behandling av diabetes
IL146579A0 (en)	2002-07-25	Process for the preparation of herbicidal derivatives
EP1343493A4 (en)	2009-06-24	USE OF (-) (3-HALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES IN THE TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA
AU8026200A (en)	2001-04-30	Treatment of heart disease with cox-2 inhibitors
HUP0103788A3 (en)	2003-05-28	Processes for the preparation of 5-hydroxy-3-oxopentanoic acid derivatives
HUP0202728A3 (en)	2003-11-28	Process for preparation of phenylacetic acid derivatives
SI1200114T1 (sl)	2009-10-31	Inhibitorji ppar delta za zdravljenje kardiovaskularnih bolezni
HUP0203025A3 (en)	2004-12-28	Treatment of migraine by using alpha-lipoic acid or derivatives thereof
AU9545701A (en)	2002-03-22	Use of carp inhibitors for the treatment of heart diseases
AU7653600A (en)	2001-04-30	Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
AU7958000A (en)	2001-05-14	Process for the preparation of oxyiminoalkanoic acid derivatives
IL154464A0 (en)	2003-09-17	Catalytic process for the preparation of thiazole derivatives
AU7568500A (en)	2001-04-24	Laser probe for medical treatment
AU1522101A (en)	2001-05-30	Heparanase inhibitors for the treatment of heart failure
MXPA01009621A (es)	2003-07-21	Procedimiento para la preparacion de acido 3s-3-amino-3-aril propionico, y derivados del mismo.
PL338742A1 (en)	2000-09-11	Method of obtaining derivatives of dioxypenicillanic acid
GB9907082D0 (en)	1999-05-19	The preparation of carboxylic acid derivatives
AU4116500A (en)	2000-11-14	The use of alpha lipoic acid in the antimetastatic treatment
ATE261965T1 (de)	2004-04-15	Bispidin-derivate zur behandlung von herzarrhythmien